Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MorningLyte: Mosunetuzumab Plus Lenalidomide vs Anti-CD20 mAb Plus Chemotherapy in Previously Untreated Follicular Lymphoma
NCT06284122Phase 3Active, not recruiting
- Sponsor
- LYSARC
- Start
- Jun 2024
- Primary completion
- Nov 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of mosunetuzumab in follicular lymphoma (FL), sponsored by LYSARC. Started Jun 2024; status: active, not recruiting.
02
Drugs
mosunetuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT06284122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06284122.